The firm recently won $4.5 million as well as approval for its Fertilome test from New York state, though some have questioned the test's clinical utility.
The company has contracted with a urologist, who will review customers' requests for tests, and prescribe the firm's epigenetics-based male fertility analysis.
The companies will recruit and track a cohort of women to study environmental, genetic, and lifestyle factors that may contribute to fertility outcomes.
Loci identified in a genome-wide association study of women with spontaneous fraternal twin birth offers clues to the hormonal processes behind this propensity.
The test uses Illumina arrays to measure genome-wide sperm DNA methylation patterns in order to predict male fertility status and resulting embryo quality.
The New York Times reports that evidence linking trauma in one generation to epigenetic effects that influence subsequent generations may be overstated.
